Rossetti, Rafaela 
; Brand, Heloisa ; Lima, Sarah Caroline Gomes de ; Furtado, Izadora Peter ; Silveira, Roberta Maraninchi ; Fantacini, Daianne Maciely Carvalho; Covas, Dimas Tadeu ; Souza, Lucas Eduardo Botelho de
Source: Immunotherapy Advances. Unidade: FMRP
Subjects: IMUNOTERAPIA, NEOPLASIAS, SISTEMA IMUNE, TRANSDUÇÃO DE SINAL CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROSSETTI, Rafaela et al. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunotherapy Advances, v. 2, n. 1, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.1093/immadv/ltac005. Acesso em: 26 jan. 2026.APA
Rossetti, R., Brand, H., Lima, S. C. G. de, Furtado, I. P., Silveira, R. M., Fantacini, D. M. C., et al. (2022). Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunotherapy Advances, 2( 1), 1-14. doi:10.1093/immadv/ltac005NLM
Rossetti R, Brand H, Lima SCG de, Furtado IP, Silveira RM, Fantacini DMC, Covas DT, Souza LEB de. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer [Internet]. Immunotherapy Advances. 2022 ; 2( 1): 1-14.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1093/immadv/ltac005Vancouver
Rossetti R, Brand H, Lima SCG de, Furtado IP, Silveira RM, Fantacini DMC, Covas DT, Souza LEB de. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer [Internet]. Immunotherapy Advances. 2022 ; 2( 1): 1-14.[citado 2026 jan. 26 ] Available from: https://doi.org/10.1093/immadv/ltac005
